Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter Retrospective Study

摘要

Background.Rituximab plus bendamustine (R‐B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R‐CHOP to R‐B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R‐CHOP or R‐B in five European cancer centers and compared their outcomes.